Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoids vs placebo for acute exacerbation of idiopathic pulmonary fibrosis
2024-514799-42-00Phase 2Authorised
- Sponsor
- Groupe hospitalier Paris Saint-Joseph
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Glucocorticoids with Placebo (2 arms). Primary endpoint: All-cause mortality rate at Day 30. Planned start Nov 2024; status: authorised.
02
Drugs
methylprednisoloneprednisone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-514799-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514799-42-00.